PROBUCOL IN HYPERCHOLESTEROLEMIA - A DOUBLE-BLIND-STUDY
PROBUCOL IN HYPERCHOLESTEROLEMIA - A DOUBLE-BLIND-STUDY
复制标题
DOI：
10.1016/0021-9150(80)90229-4
复制
发表时间：
1980-01-01
期刊：
影响因子：
5.3
通讯作者：
MORDASINI, R
中科院分区：
文献类型：
--
作者：
RIESEN, WF;KELLER, M;MORDASINI, R
本文观察了普罗布考对27例原发性高胆固醇血症患者血脂、脂蛋白及载脂蛋白A1、A2、B的影响。3个月后。的饮食治疗和6周的安慰剂期，患者接受4 ×普罗布考或安慰剂每天250 mg，持续4个月。在双盲设计中。总胆固醇和LDL[低密度脂蛋白]-胆固醇显着降低普罗布考（分别为13%和16%），除了饮食。载脂蛋白B下降12%。HDL [高密度脂蛋白]胆固醇浓度、血清甘油三酯和富含甘油三酯的脂蛋白没有显着改变。普罗布考治疗后，载脂蛋白A1和A2明显降低。患者对药物的主观和客观耐受性良好。
The effect of probucol on serum lipids, lipoproteins and the apoproteins A1, A2 and B was studied in 27 patients with primary hypercholesterolemia. After 3 mo. of dietary treatment and a 6 wk placebo period the patients received 4 .times. 250 mg of probucol or placebo per day for 4 mo. in a double blind design. Total and LDL[low density lipoprotein]-cholesterol were significantly reduced with probucol (13% and 16%, respectively) in addition to the diet. Apo B showed a 12% decrease. The HDL [high density lipoprotein] cholesterol concentration, serum triglycerides and triglyceride-rich lipoproteins were not significantly altered. Apo A1 and Apo A2 were markedly reduced under probucol treatment. The subjective and objective tolerance of the drug was good.